Conventional pre-clinal human disease models are usually developed based on 2D cell culture or animal models. Due to the limitations such as differences in species, low throughput and/or lack of in vivo complexities, these models are susceptible to increase the failure rate and the cost in the pre-clinical discovery of new drugs as well as the validation of therapeutic efficacy. With the advancement of organoids, microfluidic and 3D printing technologies, we have witnessed the significant progress in creating the microphysiological environment for organs-on-chips. The recently passed US FDA moderisation act 2.0 has implemented the microphysiological systems as alternative evaluations of drug regulation pathways. We therefore envisage the advanced human models integrated with stat-of-the-art bioanalytical technologies become powerful tools in the discovery of new drugs and therapeutic modalities towards the personalized therapy.
This Research Topic welcomes publications including original research articles in full length, short communications, review articles, opinions and perspectives covering the recent advances and challenges in the following categories.
1. The state-of-the-art techniques to develop in-vitro or ex-vivo models that can recapitulate key characteristics of various diseases.
2. The state-of-the-art techniques for sensing or imaging specific biomarkers associated with the onset and progression of disease within in-vitro or ex-vivo disease models.
3. The discovery of novel drugs and therapeutic modalities within the patient-derived in-vitro or ex-vivo disease models, particularly in using the state-of-the-art bioanalytical techniques (e.g. biosensing or bioimaging).
The themes of this Research Topic include but are not limited to:
• Development of advanced in vitro and ex vivo disease models
• Microfluidic organ/organoid-on-chip
• Biosensing and bioimaging for 3D human disease models
• Bioanalytical techniques for 3D human disease models
• Drug discovery and screening based on human models
• Validation of therapeutic modalities (e.g. chemotherapy, immunotherapy, and radiation therapy) based on human models
Conventional pre-clinal human disease models are usually developed based on 2D cell culture or animal models. Due to the limitations such as differences in species, low throughput and/or lack of in vivo complexities, these models are susceptible to increase the failure rate and the cost in the pre-clinical discovery of new drugs as well as the validation of therapeutic efficacy. With the advancement of organoids, microfluidic and 3D printing technologies, we have witnessed the significant progress in creating the microphysiological environment for organs-on-chips. The recently passed US FDA moderisation act 2.0 has implemented the microphysiological systems as alternative evaluations of drug regulation pathways. We therefore envisage the advanced human models integrated with stat-of-the-art bioanalytical technologies become powerful tools in the discovery of new drugs and therapeutic modalities towards the personalized therapy.
This Research Topic welcomes publications including original research articles in full length, short communications, review articles, opinions and perspectives covering the recent advances and challenges in the following categories.
1. The state-of-the-art techniques to develop in-vitro or ex-vivo models that can recapitulate key characteristics of various diseases.
2. The state-of-the-art techniques for sensing or imaging specific biomarkers associated with the onset and progression of disease within in-vitro or ex-vivo disease models.
3. The discovery of novel drugs and therapeutic modalities within the patient-derived in-vitro or ex-vivo disease models, particularly in using the state-of-the-art bioanalytical techniques (e.g. biosensing or bioimaging).
The themes of this Research Topic include but are not limited to:
• Development of advanced in vitro and ex vivo disease models
• Microfluidic organ/organoid-on-chip
• Biosensing and bioimaging for 3D human disease models
• Bioanalytical techniques for 3D human disease models
• Drug discovery and screening based on human models
• Validation of therapeutic modalities (e.g. chemotherapy, immunotherapy, and radiation therapy) based on human models
